• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 28, 2023 at 11:02: AM
via Acumen Pharmaceuticals plans to conduct a Phase II or Phase II/III clinical trial investigating the monoclonal antibody ACU193 in patients with early Alzheimer’s disease (AD), says president and CEO Daniel O’Connell. The company expects to initiate the next phase trial in 2024.

article source
 




Top Bottom
Back
Quote